Rockwell Medical Reports Second Quarter Results

WIXOM, Mich., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the quarter and six months ended June 30, 2017.

Q2 2017 Financial Highlights

Sales were $13.2 million compared to $13.4 in Q2 2016.